Novel drugs, drug sequences and combinations have improved the outcome of prostate
cancer in recent years. The latest approvals include abiraterone acetate, enzalutamide and …

Prostate cancer (PCa) is the most frequently occurring type of malignant tumor and a leading
cause of oncological death in men. PCa is very heterogeneous in terms of grade …

Synthetic biology applied to industrial biotechnology is transforming the way we produce
chemicals. However, despite advances in the scale and scope of metabolic engineering, the …

Prostate cancer–specific positron emission tomography (pcPET) has been shown to detect
sites of disease recurrence at serum prostate-specific antigen (PSA) levels that are lower …

Prostate cancer (PCa) is the second most diagnosed cancer in men worldwide. For its
screening, serum prostate specific antigen (PSA) test has been largely performed over the …

Urine contains extracellular vesicles (EVs) that concentrate molecules and protect them from
degradation. Thus, isolation and characterisation of urinary EVs could increase the …

Early detection and diagnosis of cancer can allow timely medical intervention, which greatly
improves chances of survival and enhances quality of life. Biomarkers play an important role …

Prostate cancer (PCa) is the most common non-cutaneous cancer in men. The androgen
receptor (AR), a ligand-activated transcription factor, constitutes the main drug target for …

Introduction: Metabolomics, the study of metabolites, is a promising research field for
cancers. The metabolic pathway in a tumor cell is different from a normal tissue cell. There …

Simple Summary The lack of highly specific and sensitive biomarkers for the early detection
of prostate cancer (PCa) is a major barrier to its management. Volatilomics emerged as a …